Twin Capital Management Inc. Buys 101 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Twin Capital Management Inc. raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,655 shares of the biopharmaceutical company’s stock after acquiring an additional 101 shares during the quarter. Twin Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,604,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $28,000. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares during the period. Avalon Trust Co purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $36,000. Crowley Wealth Management Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $36,000. Finally, Private Wealth Management Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 39 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $573.45 on Monday. The firm’s fifty day moving average is $676.70 and its two-hundred day moving average is $776.59. Regeneron Pharmaceuticals, Inc. has a 52-week low of $536.30 and a 52-week high of $1,211.20. The company has a market cap of $62.69 billion, a P/E ratio of 14.98, a P/E/G ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $11.86 earnings per share. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.61%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on REGN. Sanford C. Bernstein decreased their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Bernstein Bank decreased their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. dropped their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a report on Monday, March 31st. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.